Benjamin Levy, MD

Articles

Receiving Molecular Testing Results for NSCLC

November 2nd 2022

Bhuvana Ramkumar, MD, and Neil Morganstein, MD, share if they believe there should be a standard for molecular testing reports, and how frequently they communicate with their patients during the process.

Integrating Molecular Testing Results into Electronic Medical Records

November 2nd 2022

The panel reflects on challenges with the EMR, and the impact it has on treatment decision making for their patients with NSCLC.

Using Liquid Biopsy for Molecular Testing in NSCLC

October 26th 2022

Bhuvana Ramkumar, MD, highlights the strengths of liquid biopsy for molecular testing in NSCLC.

Types of Tissue Next-Generation Sequencing Platforms in NSCLC

October 26th 2022

Experts discuss the types of genotype panels they often use for testing patients with NSCLC, and why.

Average Turnaround Time for NSCLC Molecular Testing

October 19th 2022

Dr Neil Morganstein explains the typical turnaround times for molecular testing he sees and the challenges that prolong the process.

Best Practices for Accurate Tissue Genotyping in NSCLC

October 19th 2022

Dr Bhuvana Ramkumar shares best practices for molecular testing in NSCLC to obtain the most accurate results.

Enhancing Communication Among the Multidisciplinary Care Team

October 12th 2022

Bhuvana Ramkumar, MD, and Neil Morganstein, MD, share standards of communication among the care team at their clinical practice sites.

Challenges With and Strategies for Tissue Procurement in NSCLC

October 12th 2022

Drs Benjamin Levy, Neil Morganstein, and Bhuvana Ramkumar discuss challenges of procuring for molecular testing in patients with NSCLC.

Dr. Levy on the Approval of Trastuzumab Deruxtecan in HER2-Mutant NSCLC

August 19th 2022

Benjamin Levy, MD, discusses the significance of the FDA approval of fam-trastuzumab deruxtecan-nxki in HER2-mutant non–small cell lung cancer.

Dr. Levy on the Efficacy of Datopotamab Deruxtecan Plus Pembrolizumab in NSCLC

August 9th 2022

Benjamin Levy, MD, discusses the efficacy findings of the combination of datopotamab deruxtecan and pembrolizumab, with or without chemotherapy, in non–small cell lung cancer.

Updated efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer

July 13th 2022

Dr Levy presents updated safety and efficacy results on larotrectinib in patients with TRK fusion-positive lung cancer.

Long-term efficacy and safety of larotrectinib in a pooled analysis of patients with tropomyosin receptor kinase (TRK) fusion cancer

July 13th 2022

Dr Benjamin Levy reviews long-term, pooled safety and efficacy data on larotrectinib in patients with TRK fusion-positive cancers.

Closing Expert Perspectives on Treatment in Advanced NSCLC

June 2nd 2022

Lung cancer experts share final thoughts on their thorough discussion of treatments in NSCLC and what to look for in the future.

Emerging Antibody Drug Conjugates in the Lung Cancer Treatment Landscape

June 2nd 2022

Dr Martin Dietrich gives an overview of novel antibody-drug conjugates in the NSCLC treatment landscape.

Recent Advances in Treatment of ROS1-Rearranged NSCLC

May 25th 2022

Hatim Hussain, MD, explains emerging data on ROS1 rearrangements in NSCLC and his approach to treatment in his clinical practice.

Updates in Treatment of NSCLC with ALK Rearrangements

May 25th 2022

Oncologists review data from the ALTA-1L clinical trial and CROWN study on therapies for the treatment of ALK rearrangements.

Testing for TRK Fusions at Diagnosis and Progression in NSCLC

May 17th 2022

Drs Fernando C. Santini and Hatim Hussain explain how they approach testing and treatment of patients with TRK fusion at diagnosis and progression in non–small cell lung cancer.

Treatment Selection and Sequencing for Patients with NTRK Fusions in Clinical Practice

May 17th 2022

A panel of lung cancer experts illustrate their personal clinical experience with treatment selection and sequencing for treating patients who have NTRK fusions.

Recent Advances in Treatment of NSCLC with NTRK Fusions

May 11th 2022

Misako Nagasaka, MD, PhD, provides an overview of clinical trial data on treatments for NTRK fusion–positive lung cancer.

Treatment of KRAS G12C Mutant NSCLC

May 11th 2022

Benjamin Levy, MD, explains KRAS G12C mutations in non–small cell lung cancer, and Hatim Husain, MD, provides insight into the mechanism of action of G12C inhibitors.